Biol Blood Marrow Transplant. 2012; 18(3):348–371.2 2. Martin PJ, Counts GW Jr, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010; 28(6):1011–1016.
3 3. Hammond C, Abrams JR, Syrjala KL. Fertility and risk factors for elevated infertility concern in 10‐year hematopoietic cell transplant survivors and case‐matched controls. J Clin Oncol. 2007; 25(23):3511–3517.
4 4. Littley MD, Shalet SM, Morgenstern GR, Deakin DP. Endocrine and reproductive dysfunction following fractionated total body irradiation in adults. Q J Med. 1991; 78(287):265–274.
5 5. Cust MP, Whitehead MI, Powles R, et al. Consequences and treatment of ovarian failure after total body irradiation for leukaemia. BMJ. 1989; 299(6714):1494–1497.
6 6. Corson SL, Sullivan K, Batzer F, et al. Gynecologic manifestations of chronic graft‐versus‐host disease. Obstet Gynecol. 1982; 60(4):488–492.
7 7. Practice Committee of the American Society for Reproductive Medicine. Smoking and infertility. Fertil Steril. 2004; 81(4):1181–1186.
8 8. Buchbinder D, Brazauskas R, Bo‐Subait K, et al. Predictors of Loss to Follow‐Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplant. 2020; 26(3):553–561.
9 9. Blazar RB, Murphy WJ, Abedi M. Advances in graft‐versus‐host disease biology and therapy. Nat Rev Immunol. 2012; 12:443–458.
10 10. Epstein O, Thomas HC, Sherlock S. Primary biliary cirrhosis is a dry gland syndrome with features of chronic graft‐versus‐host disease. Lancet. 1980; 1(8179):1166–1168.
11 11. Wenzel J, Lucas S, Zahn S, et al. CXCR3<–>ligand‐mediated skin inflammation in cutaneous lichenoid graft‐versus‐host disease. J Am Acad Dermatol. 2008; 58(3):437–442.
12 12. Kawasaki H, Takayama J, Ohira M. Herpes zoster infection after bone marrow transplantation in children. J Pediatr. 1996; 128:353–356.
13 13. Atkinson K, Meyers JD, Storb R, et al. Varicella‐zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation. 1980; 29:47–50.
14 14. Wainwright MS, Martin PL, Morse RP, et al. Human herpesvirus 6 limbic encephalitis after stem cell transplantation. Ann Neurol. 2001; 50(5):612–619.
15 15. Shiroshita K, Mori T, Kato J, et al. Clinical characteristics of human herpesvirus‐6 myelitis after allogeneic hematopoietic stem cell transplantation and its favorable outcome by early intervention. Bone Marrow Transplant. 2019; 55:939–945.
16 16. Youssef S, Rodriguez G, Rolston KV, et al. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine‐breakthrough infections, 1989–2005. Medicine (Baltimore). 2007; 86:69–77.
17 17. Hoyle C, Goldman JM. Life‐threatening infections occurring more than 3 months after BMT. 18 UK Bone Marrow Transplant Teams. Bone Marrow Transplant. 1994; 14:247–252.
18 18. Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA. Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood. 1990; 75:1583–1586.
19 19. Kulkarni S, Powles R, Treleaven J, et al. Chronic graft‐versus‐host‐disease is associated with long‐term risk for pneumococcal infections in recipients of bone marrow transplants. Blood. 2000; 95:3683–3686.
20 20. Alonso CD, Treadway SB, Hanna DB, et al. Epidemiology and outcomes of clostridium difficile infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2012; 54(8):1053–1063.
21 21. Joseph RW, Couriel DR, Komanduri KV. Chronic graft‐versus‐host disease after allogeneic stem cell transplantation: challenges in prevention, science, and supportive care. J Support Oncol. 2008; 6:361–372.
22 22. Creamer D, Martyn‐Simmons CL, Osborne G, et al. Eczematoid graft‐vs‐host disease: a novel form of chronic cutaneous graft‐vs‐host disease and its response to psoralen UV‐A therapy. Arch Dermatol. 2007; 143:1157–1162.
23 23. Sullivan KM, Shulman HM, Storb R, et al. Chronic graftversus‐host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981; 57(2):267–276.
24 24. Jacobsohn DA, Kurland BF, Pidala J, et al. Correlation between NIH composite skin score, patient‐reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood. 2012; 120:2545–2552.
25 25. Patel AR, Turner ML, Baird K, et al. Voriconazole induced phototoxicity masquerading as chronic graft‐versus‐host disease of the skin in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2009; 15(3):370–376.
26 26. Rizzo JD, Wingard JR, Tichelli A, et al. Recommended screening and preventive practices for long‐term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2006; 12:138–151.
27 27. Schubert MM, Sullivan KM. Recognition, incidence, and management of oral graft‐versus‐host disease. NCI Monogr. 1990;( 9):135–143.
28 28. National Cancer Institute. Oral and Dental Management Before Cancer Therapy. 2013. Available from: http://www.cancer.gov/cancertopics/pdq/supportivecare/oralcomplications/HealthProfessional/page3 (accessed 24 August 2020).
29 29. Picciotto A, Campo N, Brizzolara R, et al. Chronic hepatitis induced by Jin Bu Huan. J Hepatol. 1998; 28:165–167.
30 30. Harvey J, Colin‐Jones DG. Mistletoe hepatitis. Br Med J ( Clin Res Ed). 1981; 282:186–187.
31 31. Centers for Disease Control and Prevention (CDC). Hepatic toxicity possibly associated with kava‐containing products – United States, Germany, and Switzerland, 1999–2002. MMWR Morb Mortal Wkly Rep. 2002; 51:1065–1067.
32 32. Majhail NS, DeFor T, Lazarus HM, Burns LJ. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors. Biol Blood Marrow Transplant. 2008; 14:790–794.
33 33. Akpek G, Chinratanalab W, Lee LA, et al. Gastrointestinal involvement in chronic graft‐versus‐host disease: a clinico pathologic study. Biol Blood Marrow Transplant. 2003; 9(1):46–51.
34 34. Spiryda LB, Laufer MR, Soiffer RJ, Antin JA. Graft‐versus‐host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant. 2003; 9(12):760–765.
35 35. Grigg AP, Underhill C, Russell J, Sale G. Peyronie’s disease as a complication of chronic graft versus host disease. Hematology. 2002; 7(3):165–168.
36 36. Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015; 21(3):389–401.
37 37. Choi M, Sun CL, Kurian S, et al. Incidence and predictors of delayed
